- Home
- TYL vs ILMN Comparison
TYL vs ILMN Comparison
Compare TYL & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYL
- ILMN
- Stock Information
- Founded
- TYL 1966
- ILMN 1998
- Country
- TYL United States
- ILMN United States
- Employees
- TYL N/A
- ILMN N/A
- Industry
- TYL Computer Software: Prepackaged Software
- ILMN Medical Specialities
- Sector
- TYL Technology
- ILMN Health Care
- Exchange
- TYL Nasdaq
- ILMN Nasdaq
- Market Cap
- TYL 23.7B
- ILMN 16.0B
- IPO Year
- TYL N/A
- ILMN 2000
- Fundamental
- Price
- TYL $530.01
- ILMN $103.03
- Analyst Decision
- TYL Buy
- ILMN Buy
- Analyst Count
- TYL 11
- ILMN 15
- Target Price
- TYL $688.27
- ILMN $123.67
- AVG Volume (30 Days)
- TYL 282.1K
- ILMN 1.3M
- Earning Date
- TYL 10-22-2025
- ILMN 11-03-2025
- Dividend Yield
- TYL N/A
- ILMN N/A
- EPS Growth
- TYL 44.59
- ILMN N/A
- EPS
- TYL 6.99
- ILMN 7.91
- Revenue
- TYL $2,245,750,000.00
- ILMN $4,284,000,000.00
- Revenue This Year
- TYL $10.86
- ILMN N/A
- Revenue Next Year
- TYL $9.28
- ILMN $2.76
- P/E Ratio
- TYL $75.78
- ILMN $13.06
- Revenue Growth
- TYL 10.69
- ILMN N/A
- 52 Week Low
- TYL $513.52
- ILMN $68.70
- 52 Week High
- TYL $661.31
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- TYL 35.25
- ILMN 57.64
- Support Level
- TYL $532.47
- ILMN $95.12
- Resistance Level
- TYL $543.30
- ILMN $104.22
- Average True Range (ATR)
- TYL 9.80
- ILMN 3.33
- MACD
- TYL -2.22
- ILMN 0.47
- Stochastic Oscillator
- TYL 4.99
- ILMN 88.42
About TYL Tyler Technologies Inc.
Tyler Technologies provides a full suite of software solutions and services that address the needs of cities, counties, schools, courts and other local government entities. The company's three core products are Munis, which is the core ERP system, Odyssey, which is the court management system, or CMS, and payments. The company also provides a variety of add-on modules and offers outsourced property tax assessment services.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.